We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cushing's Disease Complications (COMPLICUSHING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02568982
Recruitment Status : Completed
First Posted : October 6, 2015
Last Update Posted : January 29, 2020
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study aims at investigating the complications of Cushing's disease in "de novo" patients. A series of investigations will assay before treatment and every year thereafter during a 3 years follow-up period the various complications of the disease. These investigations will determine the presence and severity of cardiovascular, metabolic, and bone complications as well as the Quality of Life. Outcome of these complications after treatment, especially after pituitary surgery will be monitored, as well as cortisol levels.

Condition or disease Intervention/treatment
Cushing's Disease Other: Exams and questionnaires

Detailed Description:

At inclusion the following will be investigated and recorded :

  • demographic and personal medical history.
  • Familial medical history related to osteoporosis, cardiovascular disorders and thromboembolism.
  • Current medical treatment.
  • Physical examination.

  • Assessment of basal 24hrs urinary cortisol and salivary cortisol.

    - At baseline (i.e. before specific treatment of Cortisol excess):

  • physical examination,
  • routine biology,
  • HbA1C, fasting glucose and oral glucose load,
  • cholesterol, triglyceride, HDL & LDL,
  • coagulation and fibrinolysis investigation,
  • 24hrs urinary cortisol and salivary cortisol, urinary labstick test.
  • EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US,
  • ophthalmology examination,
  • spine X-Ray, bone densitometry,
  • QoL questionnaires (SF-36, QoLCushing, Beck BDI-II).

Every year during a 3 years follow-up the following will be investigated :

  • Current medical treatment.
  • Physical examination.
  • Assessment of basal routine biology,
  • HbA1C, fasting glucose,
  • cholesterol, triglyceride, HDL & LDL,
  • coagulation and fibrinolysis investigation,
  • 24hrs urinary cortisol and salivary cortisol, urinary labstick test.
  • EKG, cardiac ultrasound, cardiac CT-scan (if abnormal initially), arterial and venous US,
  • ophthalmology examination, bone densitometry,
  • QoL questionnaires (SF-36, QoLCushing, Beck BDI-II).
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease
Actual Study Start Date : September 21, 2015
Actual Primary Completion Date : December 20, 2019
Actual Study Completion Date : December 20, 2019

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
patient with Cushing's disease Other: Exams and questionnaires
Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. number of complications (hormonal and imaging results, quality of life) per patient (composite) [ Time Frame: from diagnosis until 3 years of treatment ]

    Evaluate the frequency of :

    • metabolic complications (HbA1C, fasting glucose and oral glucose load, cholesterol, triglyceride, HDL & LDL, coagulation and fibrinolysis investigation, 24hrs urinary cortisol and salivary cortisol, urinary labstick test)
    • cardiovascular thromboembolic complications (EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US)
    • bone complications (spine X-Ray, bone densitometry)
    • quality of life alteration measured by questionnaires (SF36, QoLCushing, Beck BDI-II)


Secondary Outcome Measures :
  1. Remission rate of Cushing's disease [ Time Frame: 1 year after treatment ]

Biospecimen Retention:   Samples With DNA
blood Urinary salivary

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Cushing 's disease
Criteria

Inclusion Criteria:

  • Cushing's disease diagnosed by complementary explorations according to the National Program of Diagnosis and Care of the Cushing 's disease

Exclusion Criteria:

  • other cause of Cushing's syndrome
  • known inherited syndrome having for consequence an hormonal hypersecretion (NEM-1, complexe of carney, McCuneAlbright syndrome)
  • patient does not understand french
  • life expectancy of less than 6 months
  • pregnant women
  • dependent patient
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02568982


Locations
Layout table for location information
France
AP-HP, Hôpital Cochin
Paris, France, 75014
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Jerome Bertherat, MD, PhD Assistance Publique - Hôpitaux de Paris
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02568982    
Other Study ID Numbers: P120132
First Posted: October 6, 2015    Key Record Dates
Last Update Posted: January 29, 2020
Last Verified: January 2020
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Cushing's disease
Quality of life
Metabolic
patients with Cushing's disease
 cardiovascular
thromboembolic
bone complications
Additional relevant MeSH terms:
Layout table for MeSH terms
ACTH-Secreting Pituitary Adenoma
Pituitary ACTH Hypersecretion
Hyperpituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Endocrine System Diseases
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Pituitary Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site